Literature DB >> 16148554

FAS promoter polymorphisms correlate with activity grade in hepatitis C patients.

Dorian McIlroy1, Ioannis Théodorou, Vlad Ratziu, Dominique Vidaud, Philippe Pellet, Patrice Debré, Thierry Poynard.   

Abstract

OBJECTIVE: Hepatocytes are susceptible to FAS-mediated apoptosis. The impact of polymorphisms in the FAS gene on histopathological features of HCV infection was therefore investigated. DESIGN/
METHODS: Three single-nucleotide polymorphisms in the FAS promoter were assessed in 190 patients with chronic hepatitis C. Associations between FAS haplotypes and fibrosis stage and activity grade were tested by univariate and multivariate analyses.
RESULTS: While there was no correlation between FAS promoter genotype and fibrosis stage, patients carrying the GCA haplotype (P=0.03, Fisher's exact test) and those homozygous for the GTG haplotype (P = 0.06) tended to have lower activity scores. Logistic regression showed that these associations were independent of patient age, sex and alcohol consumption. In a logistic regression model incorporating only male gender (odds ratio 2.1, 95% confidence interval 1.1-4.1 P = 0.04), the presence of the GCA haplotype (OR 0.31 95% CI 0.13-0.78 P = 0.01), and GTG homozygosity (OR 0.26 95% CI 0.08-0.83 P = 0.02), all three factors were independently correlated with activity grade. Furthermore, the GTG haplotype appeared to have lower promoter activity than the wild type GTA haplotype in a hepatocellular carcinoma cell line.
CONCLUSIONS: Genetic polymorphism in the FAS gene may account for some of the histopathological variability in chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148554     DOI: 10.1097/00042737-200510000-00012

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  3 in total

1.  Polymorphisms within Fas gene are not associated with occult hepatitis B virus infection: Polymorphisms within Fas gene in occult HBV infection.

Authors:  Mohammad Kazemi Arababadi; Adel Mohammadzadeh; Ali Akbar Pourfathollah; Derek Kennedy
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

2.  Genetic Polymorphisms of Fas/FasL Promoter Associated with Hepatitis C cirrhosis and HCC

Authors:  Sally Abed; Mohamed El-Dosoky; Maysaa El Sayed Zaki; Mohamed EL-Shafey
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26

3.  P53 rs1042522 and CD95 rs1800682 genetic variations in HCV-4a response to antiviral therapy.

Authors:  Ahmed A Abd-Rabou; Emad F Eskander; Mervat S Mohamed; Shaymaa M M Yahya; Ashraf El Sherbini; Olfat G Shaker
Journal:  Genes Dis       Date:  2015-02-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.